Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

39.10
+0.17000.44%
Post-market: 39.500.4000+1.02%19:57 EST
Volume:3.32M
Turnover:130.54M
Market Cap:3.78B
PE:-8.22
High:40.17
Open:38.18
Low:38.15
Close:38.93
52wk High:63.45
52wk Low:38.15
Shares:96.69M
Float Shares:94.20M
Volume Ratio:1.01
T/O Rate:3.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.7595
EPS(LYR):-6.4700
ROE:-25.60%
ROA:-13.49%
PB:2.29
PE(LYR):-6.04

Loading ...

Movement Alert|CRISPR Therapeutics AG Intraday Rise 5.28%, clinical pipeline updates and a reiterated Buy rating support the rebound

Market Focus
·
Nov 18

CRISPR Therapeutics (CRSP) Could Be 46% Undervalued After Fresh CTX310 Data

Simply Wall St.
·
Nov 18

Movement Alert|CRISPR Therapeutics AG Falls 5.2% in Regular Trading, Buy-Rating Reiteration Fails to Lift Shares

Market Focus
·
Nov 17

H.C. Wainwright Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 17

Seawolf Therapeutics: Series a Financing by Versant Ventures, Mpm Bioimpact, Novartis Venture Fund, Eli Lilly, Crispr Therapeutics & Others

THOMSON REUTERS
·
Nov 16

Positive Trial Data Might Change The Case For CRISPR Therapeutics Stock

Simply Wall St.
·
Nov 13

CRISPR Therapeutics Advances Gene-Editing Trial for High Blood Pressure

TIPRANKS
·
Nov 13

Movement Alert|CRISPR Therapeutics AG Intraday Decline 5.01%, valuation debate and recent earnings miss weigh on shares

Market Focus
·
Nov 12

CRISPR Therapeutics (CRSP) Stock Looks Above Fair Value On Book Value

Simply Wall St.
·
Nov 12

CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

GlobeNewswire
·
Nov 10

CRISPR Therapeutics (CRSP) Could Be 33% Undervalued As Phase 1 Data Builds Pipeline Momentum

Simply Wall St.
·
Nov 10

Needham Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 10

Crispr Therapeutics' Ctx310 Lowers Triglycerides 63% in Phase 1b Trial

Reuters
·
Nov 09

CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026

GlobeNewswire
·
Nov 09

J.P. Morgan Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 09

The CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Sales Forecasts

Simply Wall St.
·
Nov 09

Crispr Therapeutics' Zugo-Cel Shows Clinical Response in 5 of 6 Systemic Sclerosis Patients Receiving Standard Lymphodepletion

Reuters
·
Nov 08

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

GlobeNewswire
·
Nov 08

Crispr Therapeutics Grants Chief Technical Officer 90,000 Stock Options, 40,000 Restricted Stock Units

Reuters
·
Nov 07

Crispr Therapeutics Presents Zugo-Cel Lymphoma Data at ASH Annual Meeting

Reuters
·
Nov 04